|
KMID : 1025620130160010077
|
|
Korean Journal of Medical Ethics
2013 Volume.16 No. 1 p.77 ~ p.91
|
|
|
Necessities and Required Measures to Revise the KPMA’s Promotion Code
|
|
Kang Han-Cheol
|
|
|
Abstract
|
|
|
|
Although the Korean Pharmaceutical Manufacturers Association’s Promotion Code has acted as substantive binding authority in the pharmaceutical industry and the medical community, both the industry and the community currently have cast their doubtful and skeptical eyes on the Code in terms of its legitimacy. Such issue raising seems to mainly derive from the fact that the Code has many intrinsic problems including but not limited to the absence of provisions allowing physicians’ consultations and lectures and resonable compensations for them, the unrealistic case number and compensation amount of a newly marketed drug’s post marketing surveillance and the ambiguity of clinical trials-related provision. Considering the fact that such problems are hardly found in other advanced countries’ pharmaceutical promotion codes such as those of the United States and Japan, the effort to improve contents of the Code seem to be highly needed. In this context, it is time to discuss the necessity for revising the Code’s problematic provisions in order to enhance the legitimacy of the Code.
|
|
|
KEYWORD
|
|
|
KPMA promotion code, dual punishment system, physicians’ lecture and consultation, postmarketing product surveillance, financial support for IIT
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|